Pathway
Signaling by FGFR in disease
A number of skeletal and developmental diseases have been shown to arise as a result of mutations in the FGFR1, 2 and 3 genes. These include dwarfism syndromes (achondroplasia, hypochondroplasia and the neonatal lethal disorders thanatophoric dysplasia I and II), as well as craniosynostosis disorders such as Pfeiffer, Apert, Crouzon, Jackson-Weiss and Muenke syndromes (reviewed in Webster and Donoghue 1997; Burke, 1998, Cunningham, 2007; Harada, 2009). These mutations fall into four general regions of the receptor: a) the immunoglobulin (Ig)-like domain II-III linker region, b) the alternatively spliced second half of the Ig III domain, c) the transmembrane domain and d) the tyrosine kinase domain (reviewed in Webster and Donoghue, 1997). With the exception of mutations in class b), which affect only the relevant splice variant, these mutations may be present in either the 'b' or 'c' isoforms. These activating mutations affect FGFR function by altering or expanding the ligand-binding range of the receptors (see for instance Ibrahimi, 2004a), by promoting ligand-independent dimerization (for instance, Galvin,1996; Neilson and Friesel, 1996; d'Avis,1998) or by increasing the activity of the kinase domain (for instance, Webster, 1996; Naski, 1996; Tavormina, 1999; Bellus, 2000). Thus, a number of the point mutations found in FGFR receptors alter their activity without altering their intrinsic kinase activity. Many of the mutations that promote constitutive dimerization do so by creating or removing cysteine residues; the presence of an unpaired cysteine in the receptor is believed to promote dimerization through the formation of intramolecular disulphide bonds. Paralogous mutations at equivalent positions have been identified in more than one FGF receptor, sometimes giving rise to different diseases. For instance, mutation of the highly conserved FGFR2 Ser252-Pro253 dipeptide in the region between the second and third Ig domain is responsible for virtually all cases of Apert Syndrome, while paralogous mutations in FGFR1 (S252R) and FGFR3 (P250R) are associated with Pfeiffer and Crouzon syndromes, respectively. FGFR4 is unique in that mutations of this gene are not known to be associated with any developmental disorders.
Continue reading
Recently, many of the same activating mutations in the FGFR genes that have been characterized in skeletal and developmental disorders have begun to be identified in a range of cancers (reviewed in Turner and Gross, 2010; Greulich and Pollock, 2011; Wesche, 2011). The best established link between a somatic mutation of an FGFR and the development of cancer is in the case of FGFR3, where 50% of bladder cancers have mutations in the FGFR3 coding sequence. Of these mutations, which largely match the activating mutations seen in thanatophoric dysplasias, over half occur at a single residue (S249C) (Cappellen, 1999; van Rhijn, 2002). Activating mutations have also been identified in the coding sequences of FGFR1, 2 and 4 (for review, see Wesche, 2011)
In addition to activating point mutations, the FGFR1, 2 and 3 genes are subject to misregulation in cancer through gene amplification and translocation events, which are thought to lead to overexpression and ligand-independent dimerization. It is important to note, however, that in each of these cases, the amplification or translocation involve large genomic regions encompassing additional genes, and the definitive roles of the FGFR genes in promoting oncogenesis has not been totally established. In the case of FGFR1, translocation events also give rise to FGFR1 fusion proteins that contain the intracellular kinase domain of the receptor fused to a dimerization domain from the partner gene. These fusions, which are expressed in a pre-leukemic myeloproliferative syndrome, dimerize constitutively based on the dimerization domain provided by the fusion partner and are constitutively active (reviewed in Jackson, 2010).
What the reference databases state
Statements
56 statements
56 statements · 1 reference database · Subject: Signaling by FGFR in disease · Sources: Reactome
- BAG4 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- BCR participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- CEP43 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- CPSF6 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- ERLIN2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF10 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF16 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF18 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF20 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF22 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
Show the remaining 44
- FGF23 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF3 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF4 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF6 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF7 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGF9 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGFR1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGFR1OP2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGFR2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGFR3 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FGFR4 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- FRS2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- GAB1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- GAB2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- GTF2F1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- GTF2F2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- HRAS participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- LRRFIP1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- MYO18A participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- NCBP1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- NCBP2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- NRAS participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- PIK3CA participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- PIK3R1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- PLCG1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2A participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2B participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2C participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2D participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2E participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2F participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2G participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2H participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2I participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2J participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2K participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- POLR2L participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- SOS1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- STAT1 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- STAT3 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- STAT5A participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- STAT5B participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- TRIM24 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only
- ZMYM2 participates in Signaling by FGFR in diseaseProteinReactome R-HSA-1226099Inferred only